Becton, Dickinson and Company (NYSE:BDX) Stock Holdings Decreased by Bartlett & CO. Wealth Management LLC

Bartlett & CO. Wealth Management LLC decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 43,850 shares of the medical instruments supplier’s stock after selling 204 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $10,698,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ontario Teachers Pension Plan Board lifted its position in shares of Becton, Dickinson and Company by 3.8% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock worth $451,641,000 after buying an additional 68,509 shares during the last quarter. Sapient Capital LLC acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $1,295,000. Vest Financial LLC grew its position in shares of Becton, Dickinson and Company by 27.5% during the fourth quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock worth $25,115,000 after acquiring an additional 22,207 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Becton, Dickinson and Company by 69.4% in the 4th quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock worth $3,685,000 after acquiring an additional 6,190 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in Becton, Dickinson and Company by 1.1% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 714,114 shares of the medical instruments supplier’s stock valued at $174,122,000 after purchasing an additional 7,790 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $234.00 on Thursday. Becton, Dickinson and Company has a one year low of $224.00 and a one year high of $287.32. The company has a 50-day moving average of $235.36 and a two-hundred day moving average of $237.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The stock has a market cap of $67.63 billion, a price-to-earnings ratio of 51.54, a PEG ratio of 2.10 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the previous year, the business earned $2.86 EPS. The company’s revenue was up 4.6% on a year-over-year basis. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BDX. Barclays boosted their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, June 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus target price of $280.17.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction on Monday, May 13th. The shares were sold at an average price of $236.70, for a total transaction of $781,110.00. Following the sale, the executive vice president now owns 14,608 shares in the company, valued at $3,457,713.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,615 shares of company stock valued at $2,033,381. 0.31% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.